

Clinical Pharmacology of Antianginal Drugs

Editor U. Abshagen



Springer-Verlag
Berlin Heidelberg New York Tokyo

Clinical Pharmacology of Antianginal Drugs

Contributors

U. Abshagen · W.E. Adam · W. Bleifeld · D.G. Gibson
S. Heyden · H.M. Hoffmeister · P.G. Hugenholtz
O. Kraupp · C. Nienaber · P.J. Oldershaw · B.N.C. Prichard
G. Raberger · D. Redwood · I.C. Roddie · J. Schaper
W. Schaper · J. Scholtholt · M. Stauch · W.F.M. Wallace

Editor

U. Abshagen



Springer-Verlag Berlin Heidelberg New York Tokyo

Professor Dr. med. ULRICH ABSHAGEN
Leiter Produktentwicklung Therapeutica
Boehringer Mannheim GmbH
Sandhofer Straße 116
D-6800 Mannheim 31

With 81 Figures

ISBN 3-540-13110-8 Springer-Verlag Berlin Heidelberg New York Tokyo
ISBN 0-387-13110-8 Springer-Verlag New York Heidelberg Berlin Tokyo

Library of Congress Cataloging in Publication Data. Main entry under title: Clinical pharmacology of antianginal drugs. (Handbook of experimental pharmacology; vol. 76) Bibliography: p. Includes index. 1. Vasodilators. 2. Coronary heart disease – Chemotherapy. 3. Angina pectoris – Chemotherapy. 4. Peripheral vascular diseases – Chemotherapy. I. Abshagen, U.(Ulrich) II. Series: Handbook of experimental pharmacology; 76. [DNLM: 1. Coronary Circulation – drug effects. 2. Coronary Disease – physiopathology. 3. Vasodilator Agents – pharmacodynamics. W1 HA51L v. 76/WG 300 C6406] QP905.H3 vol. 76 [RC684.V38] 615:1 s [616.1'2061] 84-22133
ISBN 0-387-13110-8 (U.S.)

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically those of translation, reprinting, re-use of illustrations, broadcasting, reproduction by photocopying machine or similar means, and storage in data banks. Under § 54 of the German Copyright Law, where copies are made for other than private use, a fee is payable to "Verwertungsgesellschaft Wort", Munich.

© by Springer-Verlag Berlin Heidelberg 1985
Printed in Germany

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Product Liability: The publisher can give no guarantee for information about drug dosage and application thereof contained in this book. In every individual case the respective user must check its accuracy by consulting other pharmaceutical literature.

Typesetting, printing and bookbinding: Brühlsche Universitätsdruckerei, Giessen
2122/3130-543210

List of Contributors

- U. ABSHAGEN, Leiter Produktentwicklung Therapeutica, Boehringer Mannheim GmbH, Sandhoferstr. 16, D-6800 Mannheim
- W. E. ADAM, Abteilung Radiologie III (Nuklearmedizin) der Universität Ulm, Steinhövelstr. 9, D-7900 Ulm/Donau
- W. BLEIFELD, Direktor der Abteilung Kardiologie, II. Medizinische Klinik, Universitätskrankenhaus Eppendorf, Universität Hamburg, Martinistr. 52, D-2000 Hamburg 20
- D. G. GIBSON, Consultant Cardiologist, Brompton Hospital, Cardiac Department, Fulham Road, London WS3 6HP, Great Britain
- S. HEYDEN, Department of Community and Family Medicine, Duke University Medical Center, Division of Epidemiology and Biostatistics, Durham, NY 27710, USA
- H. M. HOFFMEISTER, Max-Planck-Institut, Department of Experimental Cardiology, Parkstr. 1, D-6350 Bad Nauheim
- P. G. HUGENHOLTZ, The Department of Cardiology, Thoraxcentrum, Academisch Ziekenhuis Rotterdam, Ziekenhuis Dijkzigt, Dr. Molewaterplein 40, NL-3015 GD Rotterdam
- O. KRAUPP, Pharmakologisches Institut der Universität Wien, Währinger Str. 13a, A-1090 Wien IX
- C. NIENABER, Abteilung für Kardiologie, II. Medizinische Klinik, Universitäts-Krankenhaus Eppendorf, Martinistr. 52, D-2000 Hamburg 20
- P. J. OLDERSHAW, Consultant Cardiologist, Brompton Hospital, Fulham Road, London SW3 6HP, Great Britain
- B. N. C. PRICHARD, Department of Clinical Pharmacology (Department of Medicine), School of Medicine, University College London, The Rayne Institute, 5 University Street, London WC1E 6 JJ, Great Britain
- G. RABERGER, Pharmakologisches Institut der Universität Wien, Währinger Str. 13a, A-1090 Wien IX
- D. REDWOOD, Consultant Cardiologist, St. Georges Hospital, Blackshaw Road, Tooting, London SW17, Great Britain
- I. C. RODDIE, Head, Physiology Department, Medical Biology Centre, The Queen's University of Belfast, 97 Lisburn Road, Belfast BT9 7BL, Northern Ireland

- J. SCHAPER, Max-Planck-Institut, Department of Experimental Cardiology,
W. G. Kerckhoff-Institut, Parkstr. 1, D-6350 Bad Nauheim 1
- W. SCHAPER, Max-Planck-Institut für physiologische und klinische Forschung,
W. G. Kerckhoff-Institut, Parkstr. 1, D-6350 Bad Nauheim 1
- J. SCHOLTHOLT, Hoechst Aktiengesellschaft, Abteilung für Pharmakologie, Post-
fach 800320, D-6230 Frankfurt 80
- M. STAUCH, Zentrum für Innere Medizin und Kinderheilkunde, Leiter der
Sektion für Kardiologie, Angiologie und Pulmonologie der Universität Ulm,
Steinhövelstr. 9, D-7900 Ulm/Donau
- W. F. M. WALLACE, Physiology Department, Medical Biology Centre, The
Queen's University of Belfast, 97 Lisburn Road, Belfast BT9 7BL, Northern
Ireland

Preface

When I was asked some years ago by the editors of the *Handbook of Experimental Pharmacology* to edit a new volume on *Antianginal Drugs*, I agreed on the condition that, in accordance with my scientific background, primary emphasis be given to clinical pharmacology and therapeutics. It soon turned out that, due to rapid developments in this field, nothing of the previous volume on *Antianginal Drugs* by Charlier (Vol. 31, 1971) could be retained apart from its basic idea of devoting considerable space to methodology.

Since editors must operate within certain limits, I had to abstain from dealing with acute myocardial infarction in detail despite the well-known overlap between unstable angina, the preinfarction syndrome, and acute myocardial infarction. It was only possible for acute myocardial infarction and the concept of reduction of infarct size to be briefly discussed within the chapter on pathophysiology of acute coronary insufficiency. The chapter on invasive methods provided an opportunity to touch on new approaches to early intervention in acute myocardial infarction. Here, intracoronary streptokinase therapy and PTCA are considered, again with attention to the overlap between mechanical and pharmacological interventions.

Although space was limited, I decided to start with a chapter on the epidemiology of coronary artery disease. It is written by a convinced and very active proponent of the risk factor concept. This was a deliberate choice in view of some controversy, such as the public discussion of the validity of this concept which has taken place particularly in Europe. At the same time this chapter offered the only opportunity in the volume to highlight the importance of both primary and secondary prevention of coronary artery disease.

The other introductory chapter is on the pathophysiology of coronary insufficiency; the principles reviewed here provide the basis for meaningful pharmacological intervention. Emphasis is given to new concepts and results in the biochemical and molecular areas and to information provided by electron microscopic studies. Furthermore, new insights into the regulation of coronary perfusion under normal and pathological conditions are dealt with. The principles of pharmacological intervention derived from these pathophysiological events during coronary insufficiency are subsequently discussed in a short overview by an eminent pharmacologist in this field.

Before dealing with the clinical pharmacology of the various groups of drugs, however, the book presents a relatively detailed set of chapters on methods for testing antianginal drugs. The purpose of this is to provide not only pharmacological information on drugs but also to present the methodological basis for

the results presented later. For those working in this field, these chapters should be of value as a reference source. They should also enable the critical reader to interpret the experimental results in light of the limitations and pitfalls of the methods used. In accordance with the theme of the volume, emphasis is given to clinical pharmacological methods. The chapter on methods in animal pharmacology is written with therapeutic needs in mind and therefore gives special attention to experiments in conscious animals.

In line with this concept, animal experiments are discussed in the pharmacological chapters only where their results are relevant to therapeutics or to an understanding of the mechanisms of action of the drugs concerned. In view of the different scientific backgrounds of the authors, the emphasis placed on pharmacology and clinical medicine varies from chapter to chapter. In addition, the space available did not allow us to deal with all aspects of the basic pharmacology of the drugs concerned. This seems justified in light of some excellent monographs that have been published recently and are recommended to the interested reader, such as volume 54 of the *Handbook* (parts I and II, 1980 and 1981) dealing with adrenergic activators and inhibitors, and the books by Fleckenstein and Roskamm *Calcium-Antagonismus* (Springer-Verlag, 1980) and by Stone and Antmann *Calcium Channel Blocking Agents in the Treatment of Cardiovascular Disorders* (Futura Publishing Company, 1983).

Although it is always difficult, if not impossible, to keep competent and distinguished authors strictly to the general theme of such a book, I hope that the original intent remains evident, namely to present current scientific views on antianginal drugs from the standpoint of clinical pharmacology and, at the same time, to provide a better understanding of the methods used and their limitations. Thus I hope that the book will prove to be a useful source of information for clinical pharmacologists, cardiologists, and internists with an interest in cardiology, and that it will aid both their scientific work and their therapeutic decision-making.

Mannheim

U. ABSHAGEN

Contents

General Principles

CHAPTER 1

Epidemiology of Ischemic Heart Disease. S. HEYDEN. With 5 Figures

A. Preface	3
B. Multiple Risk Factor Intervention Trial	4
I. Methods, Eligibility, Intervention Strategies, Randomization	4
II. Results and Interpretations	6
III. Comments	8
IV. Multiple Risk Factor Intervention in North Karelia	8
V. The WHO European Collaborative Trial	9
VI. The Oslo Trial (Primary Prevention)	10
C. Epidemiologic Observations Confirming the Trend of Decreasing Coronary Mortality in the United States	11
I. Food Consumption Pattern: United States and Germany	12
II. Development in England	12
III. Life Expectancy in the United States	13
IV. Life-Style Changes Versus Improved Medical-Surgical Care	13
V. The Rochester Study	14
VI. The Minneapolis Study	14
VII. The Chicago Peoples Gas Company Study	15
VIII. Pathologic-Anatomic Proof that Coronary Atherosclerosis is Decreasing	16
D. Hypertension and Hypercholesterolemia: Unifactorial Intervention for the Prevention of Ischemic Heart Disease	17
I. Prevention of Fatal and Nonfatal Ischemic Heart Disease Through Unifactorial Intensive Drug Therapy of Hypertension	17
II. Results	19
III. Prevention of Myocardial Infarction Through Unifactorial Treatment of Hypercholesterolemia	26
IV. Summary	33
E. Cigarette Smoking and Obesity: Unifactorial Intervention	34
I. Smoking	34
II. Obesity	36
References	42

CHAPTER 2

Pathophysiology of Coronary Circulation and of Acute Coronary Insufficiency

W. SCHAPER, J. SCHAPER, and H. M. HOFFMEISTER. With 11 Figures

A. Regulation of Coronary Blood Flow	47
I. Overview	47
II. Metabolic Autoregulation and the Adenosine Hypothesis	49
III. Alternative Hypotheses Explaining Metabolic Autoregulation . .	51
B. Coronary Artery Stenosis and Spasm	54
I. Overview	54
II. Influence of a Coronary Stenosis on Myocardial Perfusion . . .	56
C. Influence of Underperfusion on the Myocardium	58
I. Influence on Substrate Metabolism	58
II. Influence on High Energy Phosphates	61
III. Regional Contractility and Nucleotides in Reperfused Myocardium	62
IV. Effect of Regional Ischemia on Local Myocardial Function . . .	67
D. Myocardial Infarction	74
I. Mechanisms Leading to Cell Death	74
II. Reduction of Infarct Size as a Therapeutic Goal	79
References	88

CHAPTER 3

Pharmacodynamic Principles of Action of Antianginal Drugs. O. KRAUPP

A. Introduction	97
B. The Principles of "Unloading" the Heart	98
C. Groups of "Unloading Substances"	99
D. The Vasospastic Concept	101
E. Concepts Underlying Inhibition of Platelet Aggregation	102
F. Conclusion	103
I. The Augmentation of Oxygen and Substrate Supply to the Heart	103
II. Reduction of Myocardial Oxygen Demand: Improvement	
in the Economy of Cardiac Performance	104
References	105

Test Methods

CHAPTER 4

Experimental Testing of Antianginal Drugs in Animals. G. RABERGER

A. General Considerations	119
B. Measurement of Relevant Parameters	120
I. Myocardial Blood Flow	120
II. Myocardial Metabolism	127
III. Myocardial Function	130
IV. Electrocardiogram	131
V. Signal Transmission	132

C. Experimental Models	132
I. Isolated Perfused Hearts	132
II. Myocardial Underperfusion and Angina Pectoris	133
III. Myocardial Infarction	138
IV. Collateral Circulation	139
V. Reperfusion and Retroperfusion	140
D. Summary	141
References	141

CHAPTER 5

Noninvasive Methods: Systolic Time Intervals and Echocardiography

P. J. OLDERSHAW and D. G. GIBSON. With 2 Figures

A. Introduction	153
B. Systolic Time Intervals	153
I. Measurement of Systolic Time Intervals	153
II. General Points	155
III. Determinants of the Systolic Time Intervals	155
IV. Validation of Systolic Time Intervals	158
V. Use of Systolic Time Intervals to Study Drug Action with Antianginal Preparations	158
VI. Place of Systolic Time Intervals in Clinical Pharmacology	159
C. The Use of M-Mode Echocardiography in Assessing Antianginal Drugs	159
I. Technique of Recording	160
II. Technique of Measurement	161
III. Reproducibility of Dimension Measurements	161
IV. Derived Quantities	162
V. Computed Quantities	165
VI. Effect of Physiological Manoeuvres	165
VII. Effects of Drugs	166
D. Conclusions	168
References	169

CHAPTER 6

Peripheral Circulation. I. C. RODDIE and W. F. M. WALLACE. With 6 Figures

A. Assessment of Antianginal Drugs Through Studies of the Peripheral Circulation	173
B. The Use of Human Subjects for Studies on the Peripheral Circulation	174
I. Anatomical Considerations	174
II. Ethical Considerations	175
C. Administration of the Test Drug	175
I. Oral Administration	175
II. Intravenous Administration	176
III. Intra-arterial Administration	176
IV. Percutaneous Administration	177

D. Measurement of Blood Flow in the Peripheral Circulation	178
I. Venous Occlusion Plethysmography	178
II. Strain-Gauge Plethysmography	184
III. Thermal Methods	185
IV. Pulse Volume Methods	186
V. Isotope Clearance Methods	188
VI. Differentiation Between Skin and Muscle Blood Flow	188
VII. Ultrasonic Flow Meters	189
E. Measurement of Venous Tone	190
I. Volume Measurement at Constant Pressure	190
II. Pressure Measurement at Constant Volume	190
III. Vein Diameter Measurement	191
F. Measurement of Vascular Permeability	192
References	192

CHAPTER 7

Exercise Testing. D. REDWOOD. With 3 Figures

A. Introduction	197
B. Value of Stress Testing in Asymptomatic Subjects	201
C. Value of Stress Testing in Epidemiology	201
D. Indications for Exercise Testing	203
E. Safety of Stress Testing	204
I. Arrhythmias	204
II. Hypotension	204
F. The Use of Stress Testing in the Evaluation of Therapy in Patients with Ischaemic Heart Diseases	204
G. Cardiac Response to Exercise	206
H. ECG Response to Exercise	207
J. Evaluation of the Effects of Therapy	207
I. Nitrates	208
II. β -Adrenergic Blocking Drugs	209
III. Calcium Channel Blocking Drugs	209
K. Training	209
L. Summary	210
References	210

CHAPTER 8

Radionuclide Methods. W. E. ADAM and M. STAUCH. With 17 Figures

A. Clinical and Pathophysiologic Aspects of Testing Antiangial Drugs with Radionuclides	213
B. Some Important Definitions in Nuclear Medicine	215
C. Fundamentals of Nuclear Cardiology	217
I. Radionuclide Procedures for Imaging of Myocardial Perfusion	217
II. Radionuclide Procedures for Imaging of Myocardial Metabolism	219
III. Failures of Myocardial Function	219

IV. Failures of the Conduction System of the Heart and Techniques for Their Imaging	225
D. Application of Radionuclides for Testing Antianginal Drugs	226
I. β -Blockers	226
II. Vasodilators	229
References	235

CHAPTER 9

Assessment of Coronary Artery Disease and Myocardial Ischemia by Invasive Methods. C. NIENABER and W. BLEIFELD. With 18 Figures

A. Parameters for the Assessment of Cardiac Function in Ischemic Heart Disease	239
I. Introduction	239
II. Technical Aspects	241
III. Hemodynamic Monitoring	242
IV. Parameters to Evaluate Cardiac Loading Condition	243
B. Assessment of Functional Significance of Coronary Artery Disease	245
I. Indications for Coronary Arteriography	245
II. Information Gained from Coronary Angiography	247
III. Techniques of Coronary Arteriography	248
IV. Risks and Complications	249
C. Quantitative Approach to Coronary Artery Disease by Invasive Methods	250
I. Introduction	250
II. Assessment of Left Ventricular Function	251
III. Assessment of Coronary Artery Morphology	256
IV. Coronary Artery Spasm	261
V. Cardiac Metabolism in Ischemia	264
D. Invasive Techniques in Therapy	265
I. Intracoronary Thrombolysis in Acute Coronary Thrombosis	265
II. Percutaneous Transluminal Coronary Angioplasty	270
References	275

Types of Antianginal Drugs

CHAPTER 10

Organic Nitrates. U. ABSHAGEN. With 3 Figures

A. Introduction	287
B. Pharmacokinetics of Organic Nitrates	287
I. Trinitroglycerin	287
II. Isosorbide Dinitrate	292
III. Isosorbide-5-mononitrate	297
IV. Pentaerythrityl Tetranitrate	300
V. Pentaerythrityl Trinitrate	301

C. Mechanism of Action at the Molecular Level	301
I. Influence on Electrolytes	301
II. Influence on Cyclic Nucleotides	303
III. Influence on Prostaglandin Metabolism	308
D. Mechanism of Acute Antianginal Efficacy	310
I. Peripheral Haemodynamic Effects	310
II. Effects on Central Haemodynamics and Myocardial Oxygen Consumption	311
III. Effects on Myocardial Blood Flow	312
IV. Influence of Organic Nitrates on Contractility and Left Ventricular Performance	321
V. Chronotropic and Antiarrhythmic Effects	325
E. Problems of Long-Term Treatment	328
I. Nitrate Tolerance	328
II. Nitrate Dependence	334
F. Efficacy, Routes of Administration, Formulations and Dosages	335
I. Stable Angina	335
II. Unstable Angina and Variant Angina	342
References	344

CHAPTER 11

Molsidomine. J. SCHOLTHOLT. With 4 Figures

A. Chemistry – Physicochemical Properties	365
B. Metabolism – Kinetics	366
I. Metabolism and Kinetics in Animals	366
II. Metabolism and Kinetics in Humans	367
C. Pharmacology	368
I. Cardiovascular Pharmacology	368
II. Studies in Isolated Systems	372
D. Clinical Pharmacology	375
I. Hemodynamic Studies	375
II. Side Effects	376
III. Effects on Thrombocyte Aggregation In Vivo	377
IV. Effects in Hypertensive Patients	377
References	377

CHAPTER 12

 β -Adrenoceptor Blocking Agents. B. N. C. PRICHARD

A. Introduction	385
B. Pharmacodynamics	385
I. Classification of β -Blocking Drugs	385
II. The Associated Properties of β -Blocking Drugs	386
III. Blockade of Exogenous Adrenoceptor Stimulation	387
IV. Blockade of Endogenous Adrenergic Stimulation	388

V. Response to Physiological Stimuli in Patients Treated with β -Blocking Drugs	389
VI. Peripheral Resistance and Peripheral Blood Flow	391
VII. Veins	392
VIII. Regional Blood Flow	393
IX. Bronchial Smooth Muscle	394
X. Lipid Metabolism	395
XI. Glucose Metabolism	397
XII. Noradrenaline and Adrenaline	398
XIII. Renin Blocking Activity	399
XIV. Stimulation of Vasodilator Prostaglandins	400
C. Pharmacokinetics	400
I. Absorption and Metabolism	400
II. Transport and Distribution	402
III. Elimination	402
D. Basis for the Use of β -Antagonists in Ischaemic Disease	403
I. Haemodynamic Effects and Oxygen Consumption	404
II. Effect of β -Blockade on Coronary Blood Flow	406
III. Myocardial Metabolism	407
IV. Effect of β -Blocking Drugs on the Blood	408
V. Cardiac Arrhythmias	409
VI. Mode of Action of β -Blocking Drugs in Angina	410
E. Clinical Use of β -Adrenergic Blocking Drugs	410
I. Division I: Nonselective β -Blocking Drugs	410
II. Division II: Cardioselective β -Blocking Drugs	414
III. Division III: Nonselective β -Blockade plus α -Blockade	415
IV. β -Blocking Drugs in Combination with Nitrates	415
V. β -Blocking Drugs in Combination with Calcium Antagonists	416
VI. Comparison of Adrenergic Blocking Drugs	418
VII. Comparison with Other Treatment	420
VIII. Regulation of Dose in Patients with Angina Pectoris	421
IX. Indications for β -Blockade	422
X. Withdrawal of β -Blocking Drugs	423
F. Side Effects	426
I. Cardiovascular Side Effects	426
II. Respiratory Side Effects	428
III. Central Nervous System Side Effects	428
IV. Fatigue	429
V. Gastrointestinal Side Effects	429
VI. Genitourinary Side Effects	429
VII. Glucose Metabolism	429
VIII. Sensitivity Reactions	429
G. Cardioprotective Effect	430
H. Future Developments	431
J. Conclusion	431
References	432

CHAPTER 13

Calcium Antagonists. P. G. HUGENHOLTZ. With 12 Figures

A. Introduction	459
B. Mechanism of Action of Calcium Antagonists	459
C. Nifedipine	464
I. Chemistry and Pharmacokinetics	464
II. Pharmacodynamics in Humans	470
III. Clinical Experience	476
D. Diltiazem	487
I. Chemistry and Pharmacokinetics	487
II. Pharmacodynamics in Humans	493
III. Clinical Experience	496
E. Verapamil	499
I. Chemistry and Pharmacokinetics	499
II. Pharmacodynamics	502
III. Clinical Experience	508
F. Summary	514
References and Additional Reading	515

Subject Index	539
--------------------------------	-----

General Principles

